Researchers Testing Pfizer COVID Vaccine On Children As Young As 6 Months Old
Pfizer s COVID vaccine is expected to be available soon to children ages 12 to 15. Researchers are now currently testing the vaccine in kids as young as 6 months old to see if it s safe and effective.
Eloise Lacour is among the first children under 5 to receive both shots. The three-year-old is part of a study testing Pfizer s vaccine on children six months to 12 years old. Her mom, Dr. Angelica Lacour, says, Whatever we can do to protect her, even though chances are she d be totally fine if she caught the virus, we don t know what the long-term effects are.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Hazelden Betty Ford Foundation to Honor Oregon Attorney General and Stanford Professor
May 10, 2021 GMT
PORTLAND, Ore. (BUSINESS WIRE) May 10, 2021
Two pioneering women who have significantly advanced public education and dialogue around addiction and recovery will be honored as the first recipients of the Hazelden Betty Ford Foundation’s new Humanitarian Award.
Oregon Attorney General Ellen F. Rosenblum and Stanford University’s Anna Lembke, MD, will receive their awards during a virtual event May 14 from 5 p.m. to 6 p.m. PDT. Thanks to generous Hazelden Betty Ford donors, attendance is complimentary and open to all.
Alabama News
Updated:
Pfizer’s COVID vaccine is expected to be available soon to children ages 12 to 15. Researchers are now currently testing the vaccine in kids as young as 6 months old to see if it’s safe and effective.
Eloise Lacour is among the first children under 5 to receive both shots. The three-year-old is part of a study testing Pfizer’s vaccine on children six months to 12 years old. Her mom, Dr. Angelica Lacour, says, “Whatever we can do to protect her, even though chances are she’d be totally fine if she caught the virus, we don’t know what the long-term effects are.”
These updates are republished press releases and communications from members of the Science|Business Network
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
Sanofi has entered into a three-year research collaboration with Stanford University School of Medicine. Together, the two organizations and their scientists will work to advance the understanding of immunology and inflammation through open scientific exchange. Additionally, Sanofi will provide funding and scientific inputs into projects of mutual interest, crossing multiple therapeutic areas including autoimmune diseases and inflammatory conditions.
“We look forward to working with some of the most innovative scientists in the human immunology community. Together we will explore groundbreaking concepts and obtain deeper insights into underlying inflammatory disease mechanisms,” said Frank Nestle, Global Head of Research and Chief Scientific Officer, Sanofi. S